Does a Mandatory Non- medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register- based Study of 1620 Patients with Infl ammatory Arthritis

Bente Glintborg, R. Ibsen, R. E. Q. Bilbo, Merete Lund Hetland, J. Kjellberg

Original languageEnglish
Article number0205
JournalArthritis & Rheumatology
Volume71
Issue numberS10
Number of pages3
ISSN1537-2960
Publication statusPublished - 2019

Cite this